THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...

"We believe that Prolia can address a critical treatment need for patients with glucocorticoid-induced osteoporosis, which is the most common drug-induced form of the disease," said Sean E. Harper, ...

THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture ...

The MarketWatch News Department was not involved in the creation of this content. -- Bosaya(TM) and Aukelso(TM) (both denosumab-kyqq products) now available in the United States, following U.S. FDA ...

Please provide your email address to receive an email when new articles are posted on . The use of denosumab to treat osteoporosis has increased rapidly since its FDA approval in 2010, and it is now ...

THOUSAND OAKS, Calif., Nov. 5, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug awardfor Prolia™ (denosumab), a novel treatment approved in the United ...

Prolia is approved in the U.S. for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for ...

The products are expected to be available in June 2025. Osenvelt is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid ...

Bosaya™ and Aukelso™ (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation Potential benefit to the ...